Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

Claritas Pharmaceuticals Inc > Claritas Concept
View:
Post by HighSkies2019 on Feb 14, 2021 11:34am

Claritas Concept

We own the rights or lisence to R107 and let's say other big pharmas such as GW...Roche ..Novartis want to use and sell ... using technology we can give them access ...the Pharma's can produce with all labor cost at that pharma expense ...add an upcharge and sell to customers ... Claritas would have contracts with them with our set resale price... trying to set forth an example.
Comment by Scotty on Feb 15, 2021 1:12am
We have a license (correct spelling)  at the cost of millions of dollars for an unproven drug that needs further millions of dollars (funded by us through dilution)  to fund the studies needed to prove it's efficacy for its privately owned company. Tell me more about how KLY or whatever Rob apparently renamed the company (probably try and shed it's horrible history from new ...more  
Comment by Bvukmanic on Feb 15, 2021 9:43am
We already know they're trying to raise over $1 million for phase 1 (that was originally costed at $500k, then Salzman said they would pay for it), plus a years worth of g&a which is probably another $1-$2 million. Only then will they apply to get funding? WTF? So what supposedly fantastic news do they have to share? Already nearly 700 million shares after latest Salzman deal. I wonder how ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities